Zymeworks Inc Says Termination Doesn't Relieve Parties From Obligations Under Zanidatamab Zovodotin License & Collaboration Deal Accrued Prior To Termination
Portfolio Pulse from Benzinga Newsdesk
Zymeworks Inc has announced that the termination of the Zanidatamab Zovodotin License & Collaboration Deal does not relieve the parties from obligations accrued prior to the termination.
September 21, 2023 | 8:41 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Zymeworks' announcement about the termination of the Zanidatamab Zovodotin deal may cause uncertainty among investors, potentially impacting the stock negatively in the short term.
The termination of a significant deal like the Zanidatamab Zovodotin License & Collaboration can create uncertainty among investors about the company's future prospects. This uncertainty can lead to a short-term negative impact on the company's stock as investors may choose to sell their shares.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100